Related Experiment Video
Updated: May 19, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
New hepatitis C virus drug discovery strategies and model systems
Snawar Hussain1, Naina Barretto, Susan L Uprichard
1University of Illinois at Chicago, Department of Medicine, Chicago, IL 60612, USA.
Introduction:
Hepatitis C virus (HCV) is a major cause of liver disease worldwide and the leading indication for liver transplantation in the United States. Current treatment options are expensive, not effective in all patients and are associated with serious side effects. Although preclinical, anti-HCV drug screening is still hampered by the lack of readily infectable small animal models, the development of cell culture HCV experimental model systems has driven a promising new wave of HCV antiviral drug discovery.
Areas Covered:
This review contains a concise overview of current HCV treatment options and limitations with a subsequent in-depth focus on the available experimental models and novel strategies that have, and continue to enable, important advances in HCV drug development.
Expert Opinion:
With a large cohort of chronically HCV-infected patients progressively developing liver disease that puts them at risk for hepatocellular carcinoma and hepatic decompensation, there is an urgent need to develop effective therapeutics that are well tolerated and effective in all patients and against all HCV genotypes. Significant advances in HCV experimental model development have expedited drug discovery; however, additional progress is needed. Importantly, the current trends and momentum in the field suggests that we will continue to overcome critical experimental challenges to reach this end goal.
Insights
Developing new Hepatitis C virus (HCV) experimental models is crucial for discovering effective antiviral drugs. These models accelerate the identification of well-tolerated treatments for all patients and HCV genotypes.
Area of Science:
- Hepatology and Virology
- Drug Discovery and Development
Background:
- Hepatitis C virus (HCV) infection is a leading cause of liver disease and liver transplantation globally.
- Current HCV treatments face limitations including cost, efficacy, side effects, and genotype specificity.
- Preclinical drug screening for HCV is hindered by the absence of suitable small animal models.
Purpose of the Study:
- To review current Hepatitis C virus (HCV) treatment options and their limitations.
- To provide an in-depth focus on experimental models and strategies for HCV drug development.
Main Methods:
- Literature review of existing HCV therapeutics and their drawbacks.
- Analysis of current and emerging experimental models for HCV research.
- Examination of novel strategies facilitating HCV antiviral drug discovery.
Main Results:
- Cell culture-based experimental models have significantly advanced HCV antiviral drug discovery.
- Despite progress, challenges remain in developing universally effective and well-tolerated HCV therapies.
- Ongoing advancements in experimental models are critical for addressing unmet needs in HCV treatment.
Conclusions:
- There is an urgent need for novel, well-tolerated, and broadly effective Hepatitis C virus (HCV) therapeutics.
- Advances in experimental models have expedited the discovery of new anti-HCV drugs.
- Continued innovation in experimental models is essential to overcome challenges and achieve the goal of effective HCV treatment for all patients.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction
01:26Drug Discovery: Overview
01:26Human Virome